Form 4: Pediatrix Medical Group CEO James D. Swift Reports Stock Grant and Disposal
SEC Form 4
CEO James D. Swift reports acquisition of restricted shares and disposal of common stock on June 1, 2024.
Summary
- On June 1, 2024, James D. Swift, CEO of Pediatrix Medical Group, reported acquiring 105,165 shares of common stock as a grant.
- The same day, Swift disposed of 181,101 shares of common stock.
- Following these transactions, Swift beneficially owns 105,165 shares.
- The 105,165 restricted shares were granted under the company's Amended and Restated 2008 Incentive Compensation Plan.
- 25% of the restricted shares will vest on June 1, 2025, 25% on June 1, 2026, and 50% on June 1, 2027, subject to the plan's terms.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The grant of restricted shares to the CEO aligns his interests with the long-term performance of the company.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedule of the restricted shares.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the CEO's equity holdings and incentives.
Comparison to Industry Standards
- Equity grants are a common component of executive compensation packages in the healthcare industry.
- Vesting schedules are designed to retain executives and align their interests with shareholder value creation.
- Companies like HCA Healthcare, Universal Health Services, and Tenet Healthcare also utilize equity-based compensation for their executives.
Stakeholder Impact
- Shareholders may view the equity grant as a positive sign, aligning the CEO's interests with the company's long-term success.
- Employees may see the grant as a reflection of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of stock grant and disposal |
| 06/01/2025 | First vesting date (25%) of restricted shares |
| 06/01/2026 | Second vesting date (25%) of restricted shares |
| 06/01/2027 | Final vesting date (50%) of restricted shares |
| 06/04/2024 | Date of filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.